Literature DB >> 11081203

Morphological characterization and subtyping of silent somatotroph adenomas.

H Naritaka1, T Kameya, Y Sato, S Furuhata, M Otani, T Kawase.   

Abstract

GH-producing adenomas clinically are endocrine-active tumors accompanied with acromegaly in most instances. However, GH-producing adenomas apparently unassociated with acromegaly, or so-called silent somatotroph adenomas (SSA), have recently been reported but rarely. The reported cases are characterized by normal or slightly elevated serum levels of GH but without acromegaly. Tumor cells contain moderate, trace or no GH immunoreactivity. We experienced 7 cases of SSA which were not always similar in morphology and pathogenetic mechanism. They could be further divided into the following 3 subtypes. Subtype 1 (N = 2): a moderate number of cells were immunopositive for GH, and GH mRNA was also expressed in moderate or numerous cells. Densely granulated cells were noted. It is assumed that inhibition of hormone release into circulation. Subtype 2 (N = 3): a small number of cells were immunopositive for GH, while GH mRNA was expressed in numerous tumor cells. They were sparsely granulated cells containing fibrous bodies. These findings suggest that posttranslational processing of the gene product may be defective. Subtype 3 (N = 2): Only a scattered number of cells were immunopositive for GH and GH mRNA was co-localized in immunopositive cells. They were sparsely granulated cells containing poorly developed organelles that did not resemble those of typical sparsely granulated GH cells. The findings indicate that adenoma cells are largely immature with minimal GH lineage differentiation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11081203     DOI: 10.1023/a:1009942122673

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  23 in total

1.  Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.

Authors:  S X Jiang; T Kameya; Y Sato; N Yanase; H Yoshimura; T Kodama
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

2.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

3.  Corticolipotropin immunoreactivity in silent chromophobe adenomas: a light and electron microscopic study.

Authors:  J Hassoun; C Charpin; P Jaquet; J C Lissitzky; F Grisoli; M Toga
Journal:  Arch Pathol Lab Med       Date:  1982-01       Impact factor: 5.534

4.  Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation.

Authors:  P Pagesy; J Y Li; F Rentier-Delrue; O Delalande; Y Le Bouc; M Kujas; D Joubert; J Martial; F Peillon
Journal:  Acta Endocrinol (Copenh)       Date:  1990-06

5.  Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and Cushing's disease.

Authors:  T Nagaya; H Seo; A Kuwayama; T Sakurai; N Tsukamoto; T Nakane; K Sugita; N Matsui
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

6.  Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.

Authors:  R V Lloyd; K Fields; L Jin; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

7.  Apparently silent somatotroph adenomas.

Authors:  P Pagesy; J Y Li; M Kujas; F Peillon; O Delalande; A Visot; P Derome
Journal:  Pathol Res Pract       Date:  1991-12       Impact factor: 3.250

8.  Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C.

Authors:  A C Moses; M E Molitch; C T Sawin; I M Jackson; B J Biller; R Furlanetto; S Reichlin
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

9.  Heterogeneity of secretory granules of silent pituitary adenomas.

Authors:  S Holck; U M Wewer; R Albrechtsen
Journal:  Mod Pathol       Date:  1988-05       Impact factor: 7.842

10.  Ultrastructure, immunohistochemistry and hormone release of pituitary adenomas in relation to prolactin production.

Authors:  T Kameya; M Tsumuraya; I Adachi; K Abe; K Ichikizaki; S Toya; R Demura
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980
View more
  13 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 2.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

Review 3.  Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.

Authors:  Luis V Syro; Fabio Rotondo; Carlos A Serna; Leon D Ortiz; Kalman Kovacs
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Aggressive somatotrophinomas lacking clinical symptoms: neurosurgical management.

Authors:  Mario Giordano; Amir Samii; Rudolf Fahlbusch
Journal:  Neurosurg Rev       Date:  2017-12-30       Impact factor: 3.042

5.  Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity.

Authors:  Akiko Yoneda; Toshiaki Sano; Shozo Yamada; Abdulkader Obari; Zhi Rong Qian; Elaine Lu Wang; Naoko Inosita; Eiji Kudo
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

6.  Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus.

Authors:  Hiromitsu Iwata; Kengo Sato; Ryutaro Nomura; Yusuke Tabei; Ichiro Suzuki; Naoki Yokota; Mitsuhiro Inoue; Seiji Ohta; Shozo Yamada; Yuta Shibamoto
Journal:  J Neurooncol       Date:  2016-03-09       Impact factor: 4.130

7.  Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas.

Authors:  Ikuo Kobayashi; Hidehiro Oka; Heiji Naritaka; Yuichi Sato; Kiyotaka Fujii; Toru Kameya
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

8.  Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas.

Authors:  Elaine Lu Wang; Zhi Rong Qian; Shozo Yamada; Md Mustafizur Rahman; Naoko Inosita; Teruyoshi Kageji; Hideko Endo; Eiji Kudo; Toshiaki Sano
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

Review 9.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Clinically silent somatotroph adenomas are common.

Authors:  Alisha N Wade; Jennifer Baccon; M Sean Grady; Kevin D Judy; Donald M O'Rourke; Peter J Snyder
Journal:  Eur J Endocrinol       Date:  2011-04-14       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.